Aurinia Pharmaceuticals Valuation
| AUPH Stock | USD 8.86 0.01 0.11% |
At this time, the firm appears to be undervalued. Aurinia Pharmaceuticals shows a prevailing Real Value of $10.37 per share. The current price of the firm is $8.86. Our model approximates the value of Aurinia Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -0.0578, current valuation of 1.01 B, and Profit Margin of (0.10) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aurinia Pharmaceuticals' valuation include:
Price Book 3.2695 | Enterprise Value 1 B | Enterprise Value Ebitda 229.5381 | Price Sales 5.7568 | Forward PE 13.8889 |
Undervalued
Today
Please note that Aurinia Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Aurinia Pharmaceuticals is based on 3 months time horizon. Increasing Aurinia Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Aurinia Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aurinia Stock. However, Aurinia Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.86 | Real 10.37 | Target 14.0 | Hype 8.83 | Naive 8.73 |
The intrinsic value of Aurinia Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Aurinia Pharmaceuticals' stock price.
Estimating the potential upside or downside of Aurinia Pharmaceuticals helps investors to forecast how Aurinia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aurinia Pharmaceuticals more accurately as focusing exclusively on Aurinia Pharmaceuticals' fundamentals will not take into account other important factors: When choosing an evaluation method for Aurinia Pharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Aurinia Pharmaceuticals Cash |
|
Aurinia Valuation Trend
Aurinia Pharmaceuticals' real value analysis enables investors to forecast the earnings more efficiently. Using both Aurinia Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Aurinia Revenue by Product
Aurinia Pharmaceuticals Total Value Analysis
Aurinia Pharmaceuticals is presently projected to have valuation of 1.01 B with market capitalization of 1.27 B, debt of 97.61 M, and cash on hands of 391.51 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aurinia Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.01 B | 1.27 B | 97.61 M | 391.51 M |
Aurinia Pharmaceuticals Investor Information
About 43.0% of the company shares are held by institutions such as insurance companies. The book value of Aurinia Pharmaceuticals was presently reported as 2.71. The company recorded a loss per share of 0.15. Aurinia Pharmaceuticals had not issued any dividends in recent years. The entity had 1:50 split on the 23rd of October 2013. Based on the key indicators related to Aurinia Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Aurinia Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Aurinia Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aurinia Pharmaceuticals has an asset utilization ratio of 32.02 percent. This signifies that the Company is making $0.32 for each dollar of assets. An increasing asset utilization means that Aurinia Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Aurinia Pharmaceuticals Ownership Allocation
Aurinia Pharmaceuticals holds a total of 143.18 Million outstanding shares. 30% of Aurinia Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Aurinia Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 175.51 M. Net Loss for the year was (78.02 M) with profit before overhead, payroll, taxes, and interest of 83.38 M.About Aurinia Pharmaceuticals Valuation
An absolute valuation paradigm, as applied to Aurinia Stock, attempts to find the value of Aurinia Pharmaceuticals based on its fundamental and basic technical indicators. By analyzing Aurinia Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Aurinia Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aurinia Pharmaceuticals. We calculate exposure to Aurinia Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aurinia Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 161.4 M | 169.4 M | |
| Pretax Profit Margin | (0.44) | (0.46) | |
| Operating Profit Margin | (0.52) | (0.55) | |
| Net Loss | (0.44) | (0.47) | |
| Gross Profit Margin | 0.92 | 0.97 |
Aurinia Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 143.2 M | |
| Forward Price Earnings | 13.8889 |
Aurinia Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Aurinia Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Aurinia we look at many different elements of the entity such as Aurinia's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aurinia Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aurinia Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aurinia Pharmaceuticals' worth.Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |